Back to Search Start Over

Overlapping and Divergent Actions of Structurally Distinct Histone Deacetylase Inhibitors in Cardiac Fibroblasts.

Authors :
Schuetze KB
Stratton MS
Blakeslee WW
Wempe MF
Wagner FF
Holson EB
Kuo YM
Andrews AJ
Gilbert TM
Hooker JM
McKinsey TA
Source :
The Journal of pharmacology and experimental therapeutics [J Pharmacol Exp Ther] 2017 Apr; Vol. 361 (1), pp. 140-150. Date of Electronic Publication: 2017 Feb 07.
Publication Year :
2017

Abstract

Inhibitors of zinc-dependent histone deacetylases (HDACs) profoundly affect cellular function by altering gene expression via changes in nucleosomal histone tail acetylation. Historically, investigators have employed pan-HDAC inhibitors, such as the hydroxamate trichostatin A (TSA), which simultaneously targets members of each of the three zinc-dependent HDAC classes (classes I, II, and IV). More recently, class- and isoform-selective HDAC inhibitors have been developed, providing invaluable chemical biology probes for dissecting the roles of distinct HDACs in the control of various physiologic and pathophysiological processes. For example, the benzamide class I HDAC-selective inhibitor, MGCD0103 [ N -(2-aminophenyl)-4-[[(4-pyridin-3-ylpyrimidin-2-yl)amino]methyl] benzamide], was shown to block cardiac fibrosis, a process involving excess extracellular matrix deposition, which often results in heart dysfunction. Here, we compare the mechanisms of action of structurally distinct HDAC inhibitors in isolated primary cardiac fibroblasts, which are the major extracellular matrix-producing cells of the heart. TSA, MGCD0103, and the cyclic peptide class I HDAC inhibitor, apicidin, exhibited a common ability to enhance histone acetylation, and all potently blocked cardiac fibroblast cell cycle progression. In contrast, MGCD0103, but not TSA or apicidin, paradoxically increased expression of a subset of fibrosis-associated genes. Using the cellular thermal shift assay, we provide evidence that the divergent effects of HDAC inhibitors on cardiac fibroblast gene expression relate to differential engagement of HDAC1- and HDAC2-containing complexes. These findings illustrate the importance of employing multiple compounds when pharmacologically assessing HDAC function in a cellular context and during HDAC inhibitor drug development.<br /> (Copyright © 2017 by The American Society for Pharmacology and Experimental Therapeutics.)

Details

Language :
English
ISSN :
1521-0103
Volume :
361
Issue :
1
Database :
MEDLINE
Journal :
The Journal of pharmacology and experimental therapeutics
Publication Type :
Academic Journal
Accession number :
28174211
Full Text :
https://doi.org/10.1124/jpet.116.237701